<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904913</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI362B201</org_study_id>
    <nct_id>NCT04904913</nct_id>
  </id_info>
  <brief_title>A Study of IBI362 in Participants With Obesity or Overweight for Weight Loss</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of IBI362 in participants with overweight and obesity. The main purpose is to&#xD;
      learn more about how IBI362 affects body weight. The study period including 4-8 weeks dose&#xD;
      titration and 40-44 weeks maintain treatment and 12 weeks follow up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in Body Weight</measure>
    <time_frame>Baseline ,week 24</time_frame>
    <description>Percent Change from Baseline in Body Weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Body Weight</measure>
    <time_frame>Baseline ,week 48</time_frame>
    <description>Percent Change from Baseline in Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>week 61</time_frame>
    <description>Number of participants with treatment-related adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Overweight/ Obesity</condition>
  <arm_group>
    <arm_group_label>IBI362 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose IBI362 administered subcutaneously (SC) once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI362 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose IBI362 administered subcutaneously (SC) once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo administered subcutaneously (SC) once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI362 moderate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moderate dose IBI362 administered subcutaneously (SC) once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI362</intervention_name>
    <description>IBI362 administered subcutaneously (SC) once a week.</description>
    <arm_group_label>IBI362 high dose</arm_group_label>
    <arm_group_label>IBI362 low dose</arm_group_label>
    <arm_group_label>IBI362 moderate dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo administered subcutaneously (SC) once a week.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body mass Index (BMI) ≥28 kilograms per square meter (kg/m²), or ≥24 kg/m² and&#xD;
             previous diagnosis with at least one of the following comorbidities: hypertension,&#xD;
             dyslipidemia, obstructive sleep apnea&#xD;
&#xD;
          2. History of at least one unsuccessful dietary effort to lose body weight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diabetes mellitus&#xD;
&#xD;
          2. Weight change &gt; 5.0% after diet and exercise control for at least 12 weeks before&#xD;
             screening&#xD;
&#xD;
          3. Have used or are currently using weight loss drugs within 3 months before screening&#xD;
&#xD;
          4. History of pancreatitis&#xD;
&#xD;
          5. Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine&#xD;
             neoplasia syndrome type 2 (MEN-2)&#xD;
&#xD;
          6. History of moderate to severe depression，or have a history of serious mental illness&#xD;
&#xD;
          7. Any lifetime history of a suicide attempt&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>baiyi yan</last_name>
    <phone>0512-69566088</phone>
    <email>baiyi.yan@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University people's hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linong Ji</last_name>
      <phone>010-88325372</phone>
      <email>jilin@bjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

